Literature DB >> 11673415

SCA1 molecular genetics: a history of a 13 year collaboration against glutamines.

H T Orr1, H Y Zoghbi.   

Abstract

Spinocerebellar ataxia type 1 (SCA1) is a relatively rare autosomal-dominant neurological disorder. SCA1 has the intriguing feature that the disease-causing mutation is the expansion of an unstable trinucleotide repeat, specifically a CAG repeat that encodes the amino acid glutamine in ataxin-1. During the past 10 years, substantial progress has been made towards understanding the pathogenic mechanism in this disease. The nucleus has been identified as the subcellular site where the mutant protein acts to cause disease. Evidence indicates that expansion of the glutamine tract alters the folding properties of ataxin-1. Finally, several cellular pathways have been identified which are able to impinge on the SCA1 disease process. The characterization of these pathways and their role in SCA1 will guide research over the next several years.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11673415     DOI: 10.1093/hmg/10.20.2307

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  17 in total

1.  Increased susceptibility of cytoplasmic over nuclear polyglutamine aggregates to autophagic degradation.

Authors:  Atsushi Iwata; John C Christianson; Mirella Bucci; Lisa M Ellerby; Nobuyuki Nukina; Lysia S Forno; Ron R Kopito
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-02       Impact factor: 11.205

2.  Determination of Genotypic and Phenotypic Characteristics of Friedreich's Ataxia and Autosomal Dominant Spinocerebellar Ataxia Types 1, 2, 3, and 6.

Authors:  Pınar Bengi Boz; Filiz Koç; Sabriye Kocatürk Sel; Ali İrfan Güzel; Halil Kasap
Journal:  Noro Psikiyatr Ars       Date:  2016-06-01       Impact factor: 1.339

3.  Cellular fusion for gene delivery to SCA1 affected Purkinje neurons.

Authors:  K Amy Chen; Pedro E Cruz; Derek J Lanuto; Terence R Flotte; David R Borchelt; Arun Srivastava; Jianyi Zhang; Dennis A Steindler; Tong Zheng
Journal:  Mol Cell Neurosci       Date:  2011-03-17       Impact factor: 4.314

Review 4.  The roles of proteolysis and nuclear localisation in the toxicity of the polyglutamine diseases. A review.

Authors:  R Walsh; E Storey; D Stefani; L Kelly; V Turnbull
Journal:  Neurotox Res       Date:  2005       Impact factor: 3.911

5.  Parkin is an E3 ubiquitin-ligase for normal and mutant ataxin-2 and prevents ataxin-2-induced cell death.

Authors:  Duong P Huynh; Dung T Nguyen; Johannes B Pulst-Korenberg; Alexis Brice; Stefan-M Pulst
Journal:  Exp Neurol       Date:  2006-11-09       Impact factor: 5.330

6.  Genome-wide association analysis reveals putative Alzheimer's disease susceptibility loci in addition to APOE.

Authors:  Lars Bertram; Christoph Lange; Kristina Mullin; Michele Parkinson; Monica Hsiao; Meghan F Hogan; Brit M M Schjeide; Basavaraj Hooli; Jason Divito; Iuliana Ionita; Hongyu Jiang; Nan Laird; Thomas Moscarillo; Kari L Ohlsen; Kathryn Elliott; Xin Wang; Diane Hu-Lince; Marie Ryder; Amy Murphy; Steven L Wagner; Deborah Blacker; K David Becker; Rudolph E Tanzi
Journal:  Am J Hum Genet       Date:  2008-10-30       Impact factor: 11.025

Review 7.  Molecular pathogenesis of fragile X-associated tremor/ataxia syndrome.

Authors:  Christopher Raske; Paul J Hagerman
Journal:  J Investig Med       Date:  2009-12       Impact factor: 2.895

8.  Nucleation of protein aggregation kinetics as a basis for genotype-phenotype correlations in polyglutamine diseases.

Authors:  Keizo Sugaya; Shiro Matsubara
Journal:  Mol Neurodegener       Date:  2009-07-15       Impact factor: 14.195

9.  Phosphorylation of S776 and 14-3-3 binding modulate ataxin-1 interaction with splicing factors.

Authors:  Cesira de Chiara; Rajesh P Menon; Molly Strom; Toby J Gibson; Annalisa Pastore
Journal:  PLoS One       Date:  2009-12-23       Impact factor: 3.240

10.  Neuronal Atrophy Early in Degenerative Ataxia Is a Compensatory Mechanism to Regulate Membrane Excitability.

Authors:  James M Dell'Orco; Aaron H Wasserman; Ravi Chopra; Melissa A C Ingram; Yuan-Shih Hu; Vikrant Singh; Heike Wulff; Puneet Opal; Harry T Orr; Vikram G Shakkottai
Journal:  J Neurosci       Date:  2015-08-12       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.